Researchers identify information gaps about opioid antidote naloxone

November 27, 2017

The nation's opioid epidemic kills 91 people a day, according to the U.S. Centers for Disease Control and Prevention. The death toll would be even higher, were it not for emergency responders' heavy reliance on naloxone as an antidote that rapidly reverses the effects of overdose.

However, a new systematic review of evidence by clinicians and researchers at OHSU in Portland, Oregon, reveals important gaps in knowledge about the safety and effectiveness of widespread off-label use of among patients, families, friends and . The study published today in the Annals of Internal Medicine.

"Naloxone is effective, but we really need to know the best way to administer it," said senior author Roger Chou, M.D., director of the Pacific Northwest Evidence-based Practice Center at OHSU. "This has both cost and clinical implications."

The U.S. Food & Drug Administration in 2015 approved two prescription versions of naloxone - an auto-injector and a nasal spray formulation. However, many first responders have been using the less-concentrated injectable formulations of naloxone to reverse the effects of opioids. In those emergency situations, they administer it through the nose.

Such off-label permutations have been effectively used by law enforcement treating unconscious victims, but it is uncertain how much of the non-approved formulation of naloxone is absorbed and how reliably it is administered. Both of these factors could impact the effectiveness of off-label administration of naloxone compared with the more recent FDA-approved versions.

"The majority of naloxone being administered nasally is probably the non-approved formulation," said co-author Mohamud Daya, M.D., professor of emergency medicine in the OHSU School of Medicine. "The sad thing is, we don't know much about the new formulations. They've not actually been well studied in the way that you'd want them to be in a large population of patients."

One thing clinicians and first responders do know: The new FDA-approved formulations are expensive. The auto-injector, for example, carries a price tag exceeding $4,000.

Researchers reviewed 13 published studies to determine how the route of administration and dosing outside the hospital affects mortality, reversal of overdose symptoms and harm. The evidence appeared to show similar effectiveness between the intramuscular and intranasal delivery for heroin or prescription opioid overdose, but the intranasal naloxone studied was at a concentration different than the FDA-approved nasal formulation. Researchers also noted that little is known about the efficacy and safety of off-label use of naloxone for treating overdoses related to newly emerging illicit uses of more powerful opioids such as fentanyl and fentanyl derivatives.

"The off label may be fine for most overdoses related to standard heroin or prescription opioids, but may not be strong enough for these other drugs," Chou said.

It's important for new research to examine the effect of these off-label uses, he said.

"These jury-rigged intranasal devices have not been tested the same way," Chou said. "The fact that we have no evidence on the off-label uses for these devices is concerning, especially because many first responders feel compelled to use them because of the cost differences."

Explore further: Reversing opioid overdose: Concentrated naloxone nasal spray as good as injection

More information: Annals of Internal Medicine (2017). DOI: 10.7326/M17-2224

Related Stories

Reversing opioid overdose: Concentrated naloxone nasal spray as good as injection

November 16, 2017
A new study published by the scientific journal Addiction has found that a concentrated 2mg intranasal naloxone spray delivers naloxone as effectively, over the critical first 15 minutes, as the standard 0.4mg intramuscular ...

How to obtain and use the 'angel' therapeutic Naloxone

July 18, 2017
It's a terrifying scenario that's become all-too-real in the age of the opioid epidemic: a person lying lifeless, not breathing, because of an opioid overdose.

Improvised naloxone nasal sprays lack evidence of absorption and effect

February 4, 2016
Naloxone hydrochloride is a medication that can reverse the effects of an opioid overdose. First responders (peers, family, police, etc.) may prefer nasal sprays to injectable naloxone, which has led to widespread use of ...

FDA approves nasal spray to reverse narcotic painkiller overdose

November 19, 2015
(HealthDay)—A nasal spray that treats narcotic painkiller and heroin drug overdoses has been approved by the U.S. Food and Drug Administration.

Naloxone—an antidote to opioid overdose

August 31, 2016
Naloxone is an opioid antagonist, used as an "antidote" for opioid overdose which includes heroin, and opioid pain medicines such as morphine, fentanyl and codeine. It has been used since the 1970s by ambulance services and ...

Recommended for you

Drug for spinal muscular atrophy prompts ethical dilemmas, bioethicists say

December 11, 2017
When the Food and Drug Administration approved the first drug for people with spinal muscular atrophy a year ago, clinicians finally had hope for improving the lives of patients with the rare debilitating muscular disease. ...

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.